TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of bladder cancer.

OVERVIEW OF ACTIVITY
It is estimated that 81,400 new cases of bladder cancer will be diagnosed in 2020 and 17,980 deaths will be attributable to this disease. Optimal treatment of its most common form, urothelial bladder carcinoma (UBC), is dependent upon the stage and grade of the tumor and preexisting patient comorbidities. For those patients who present with or develop metastatic lesions beyond the bladder, cure is not attainable and thus the goal of therapy is to prolong quantity and quality of life. Historically, therapeutic options in this setting were largely limited to chemotherapy, but more recently a number of novel agents and strategies have yielded favorable outcomes, leading to a spate of FDA approvals and the promise that more may be forthcoming. These developments, coupled with the plethora of controversies and uncertainties plaguing the current management of UBC, provide the impetus for ongoing continuing education that seeks to enhance the knowledge of all members of the patient care team. Interprofessional collaboration is increasingly important in the provision of effective care, and prospective and retrospective patient-level research has shown that oncology nurses can play a critical role in the successful delivery of systemic therapy.

This webcast archive of a live CNE webinar symposium originally planned for the 2020 ONS Congress in partnership with the University of South Florida (USF Health) Office of Continuing Professional Development uses the perspectives of a group of leading clinical investigators and nurse practitioners to address some of the most frequently encountered questions and controversies facing clinicians involved in the management of bladder cancer and thus to help oncology nurses in the optimal application of newer, more effective options in patient care.

PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this CNE (NCPD) activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with bladder cancer.

LEARNING OBJECTIVES

• Identify available clinical trial data supporting the use of immune checkpoint inhibitors for the treatment of UBC to determine the current utility of these agents in clinical practice.
• Review available clinical trial data evaluating the use of anti-PD-1/PD-L1 antibodies as maintenance therapy after first-line chemotherapy for patients with previously untreated metastatic UBC (mUBC), and consider the potential role of this approach in routine practice.
• Appraise available research data and ongoing clinical trials evaluating novel treatment approaches with anti-PD-1/PD-L1 antibodies, and counsel appropriately selected patients about participation in active research protocols.
• Describe the frequency of fibroblast growth factor receptor (FGFR) abnormalities in patients with mUBC, and recognize the FDA approval of erdafitinib for individuals with advanced UBC and susceptible FGFR3 or FGFR2 genetic alterations whose disease has progressed during or after at least 1 line of platinum-containing chemotherapy.
• Develop an understanding of the mechanism of action of and pivotal clinical trial findings with enfortumab vedotin for previously treated locally advanced or metastatic UBC, and identify patients for whom treatment with this novel compound would be appropriate.
• Educate patients about the side effects and toxicities associated with approved therapies commonly employed in the management of UBC, and provide preventive strategies to reduce or ameliorate these toxicities.
• Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with UBC to optimize clinical and quality-of-life outcomes.

CONTACT INFORMATION
If you have questions regarding credit, please contact cpdsupport@usf.edu.

ACCREDITATION STATEMENT
USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

CME credit is no longer available for this issue

ONCC/ILNA CERTIFICATION INFORMATION
CME credit is no longer available for this issue

FOR SUCCESSFUL COMPLETION
Audio Program: This CNE activity consists of an audio component.
CME credit is no longer available for this issue

Video Program: This CNE activity consists of a video component.
CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
USF Health adheres to ACCME and ANCC standards regarding commercial support of continuing medical education. It is the policy of USF Health and Research To Practice that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Arjun Balar, MD
Associate Professor, Department of Medicine
Director, Genitourinary Medical Oncology Program
NYU Perlmutter Cancer Center
New York, New York

Consulting Agreements: AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Nektar, Pfizer Inc, Seattle Genetics; Contracted Research: AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Immunomedics Inc, Janssen Biotech Inc, Merck, Nektar, Pfizer Inc, Seattle Genetics.

Anastassia Daskalova, NP
Genitourinary Medical Oncology
Mount Sinai Hospital
New York, New York

No financial interests or affiliations to disclose.

Peter H O’Donnell, MD
Associate Professor, Department of Medicine
Section of Hematology/Oncology
Genitourinary Oncology Program
The University of Chicago
Chicago, Illinois

Consulting Agreement: Merck; Honoraria: Astellas, Atheneum Partners, FirstWord, Genentech, a member of the Roche Group, Health Advances, Janssen Biotech Inc, Merck, Schlesinger Group, Seattle Genetics, The Dedham Group; Ownership Interest: Allergan, PrescriptIQ; Paid Travel: Astellas, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Seattle Genetics; Other: Janssen Biotech Inc, Nektar, National Institutes of Health.

Susan K Roethke, CRNP, MSN, ANP-BC, AOCNP
Genitourinary Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Advisory Committee: Astellas; Speakers Bureau: Astellas, Pfizer Inc.

COURSE DIRECTOR/PANEL MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.

USF Health — USF Health CPD staff have no relevant conflicts of interest to disclose.

RTP CNE (NCPD) PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Astellas and Seattle Genetics, Genentech, a member of the Roche Group, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Merck.

Release date: September 2020
Expiration date: September 2021

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.